Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Sponsor
Sun Yat-sen University
Study ID
NCT05932264
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a phase 2, open-label study to evaluate the efficacy and safety of combination of Apatinib and Fluzoparib with or without Adebrelimab in previously-treated TP53-mutant advanced non-small cell lung cancer.

Key Dates

Start date
Jul 31, 2023
Status verified
Jun 2023
Primary completion
Jul 31, 2024
Completion
Dec 31, 2025

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: Apatinib + Fluzoparib
  • Experimental: Cohort 2: Apatinib + Fluzoparib + Adebrelimab

Primary Outcome Measure

Objective Response Rate [ Time Frame: up to 1 year ]

Central Contacts

Related Studies